DUBLIN--(BUSINESS WIRE)--The "Global Skin Cancer Diagnostics and Therapeutics Market Share - Segmented by Cancer Type, Process (Diagnosis and Treatment), and Geography - Growth, Trends, and Forecast (2018 - 2023)" report has been added to ResearchAndMarkets.com's offering.
Apart from the increasing incidence of skin cancer, factors such as favorable government initiatives, the development of novel immunotherapies, and the extension of current therapies are driving the global market for skin cancer diagnostics and therapeutics.
Despite high disease burden and major technological advantages in the field of cancer treatment, the cost of therapies remain high, and the cost of therapies for the management of skin cancer is significantly higher in comparison to other forms of cancer. High cost associated with diagnosis and management remains the major barrier for market growth, especially in developing countries.
Other factors that could potentially impede the growth of the market include a stringent regulatory environment and the lack of awareness about the disease and its progression.
Key Developments in the Market
-
FDA approved BAVENCIO (AVELUMAB), which is an injection for the
treatment of patients with locally advanced or metastatic urothelial
carcinoma. The formulation was jointly developed by Pfizer Inc. and
Merck KGaA.
- Abbott Inc.
- Agilent Technologies Inc.
- AstraZeneca PLC
- Bristol-Myers Squibb Co.
- Eli Lilly and Co.
- GlaxoSmithKline PLC
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- Qiagen N.V.
- F. Hoffmann-La Roche AG
- Sanofi S.A.
Key Topics Covered
1. Introduction
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
6. Market Dynamics
7. Market Segmentation
8. Skin Cancer Diagnostics & Therapeutics Market Key Players and Competitive Landscape
For more information about this report visit https://www.researchandmarkets.com/research/rl6d9c/the_global_skin?w=4
